AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT00107237
- Locations
- 🇺🇸
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸Duke Univaersity Medical Center, Durham, North Carolina, United States
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
- Conditions
- Interventions
- First Posted Date
- 2005-04-05
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 267
- Registration Number
- NCT00107016
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸Breastlink Medical Group Inc., Long Beach, California, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3118
- Registration Number
- NCT00106340
- Locations
- 🇩🇪
Investigative Centers, Nurnberg, Germany
🇺🇸Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Multiple Myeloma Trial in Patients With Bone Metastases
- First Posted Date
- 2005-02-23
- Last Posted Date
- 2011-06-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 179
- Registration Number
- NCT00104104
- Locations
- 🇺🇸
Osceola Cancer Center, Kissimmee, Florida, United States
🇺🇸Maryland Oncology-Hematology PA, Columbia, Maryland, United States
🇺🇸Fox Valley Hematology Oncology SC, Appleton, Wisconsin, United States
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT00103740
- Locations
- 🇬🇧
Novartis Investigative site, Oxford, United Kingdom
🇬🇧Novartis Investigative Site, London, United Kingdom
Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2005-01-31
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1007
- Registration Number
- NCT00102466
- Locations
- 🇩🇪
Investigative Centers, Nurnberg, Germany
🇨🇭Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes
- First Posted Date
- 2005-01-31
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1092
- Registration Number
- NCT00102388
- Locations
- 🇩🇪
Novartis Investigative Site, Investigative Centers, Germany
🇨🇭Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-01-14
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 527
- Registration Number
- NCT00101803
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%
- Conditions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 251
- Registration Number
- NCT00101673
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia
- Conditions
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 274
- Registration Number
- NCT00101712
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland